Table 1.

Comparison of demographic and clinical data between groups

	HT with multifocal PTC	HT with single PTC	HT alone	P
	N = 183	N = 187	N = 101
	n (%)	n (%)	n (%)
Demographic
Age	46.0 (40.0, 51.0)	41.0 (34.0, 54.0)	46.0 (32.0, 51.0)	0.989
Female	159 (86.9)	163 (87.2)	88 (87.1)	0.996
Clinical indicators
TG (ng/mL)	31.0 (21.0, 44.0)	29.0 (22.0, 44.0)	27.0 (21.0, 38.0)	0.157
Calcitonin = Normal	183 (100.0)	187 (100.0)	101 (100.0)	NA
Tumor markers (Abnormal)				NA
AFP	0 (0.0)	0 (0.0)	0 (0.0)
CA125	0 (0.0)	1 (0.6)	0 (0.0)
CA199	0 (0.0)	1 (0.6)	0 (0.0)
CEA	0 (0.0)	0 (0.0)	0 (0.0)
Ferritin	0 (0.0)	0 (0.0)	0 (0.0)
PTH = Normal	183 (100.0)	187 (100.0)	101 (100.0)	NA
Blood sugar = Abnormal	4 (2.2)	4 (2.1)	4 (4.0)	0.651
Blood lipid = Abnormal	11 (6.0)	12 (6.4)	8 (7.9)	0.819
TPOAb > 1300 (IU/mL)	130 (71.0)	22 (11.8)	48 (47.5)	< 0.001
Central compartment of cervical lymph node metastasis = Positive	124 (67.8)	97 (51.9)	0 (0.0)	0.002*
TSH (μIU/mL)	2.4 (1.6, 3.4)c	2.3 (1.6, 2.7)c	3.4 (2.6, 4.2)a,b	< 0.001
Thyroid surgery				NA
LOBE	0 (0.0)	2 (1.1)	0 (0.0)
Subtotal	0 (0.0)	0 (0.0)	101 (100.0)
Total	183 (100.0)	185 (98.9)	0 (0.0)
Number of tumors	2.0 (2.0, 2.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	< 0.001
Size of the largest tumor (cm)	0.8 (0.6, 1.2)	0.8 (0.5, 1.2)	3.6 (3.3, 3.9)	< 0.001

HT, Hashimoto’s thyroiditis; PTC, papillary thyroid carcinoma; TG, thyroglobulin; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; PTH, parathyroid hormone; TPOAb, thyroid peroxidase antibodies; TSH, thyroid-stimulating hormone; LOBE, thyroid lobectomy; Subtotal, subtotal/near-total thyroidectomy; Total, total thyroidectomy. Continuous variables were presented as median and IQR; categorical variables were presented as number and percentage.

^*HT with multifocal PTC vs. HT with single PTC.

^aSignificant difference vs. HT with multifocal PTC, P < 0.05.

^bSignificant difference vs. single PTC, P < 0.05.

^cSignificant different vs. HT alone, P < 0.05.